Cynata Therapeutics (ASX:CYP) Publishes Comparative Study on MSCs
Study Overview
Cynata Therapeutics Limited (ASX:CYP) has published a study in npj Regenerative Medicine comparing its Cymerus™ iPSC-derived MSCs to conventional MSCs from various sources. The research, led by Dr Margeaux Hodgson-Garms and Prof Jess Frith at Monash University, Melbourne, examined the secretomes of MSCs derived from iPSCs, bone marrow, adipose tissue, and umbilical cord under different conditions.
Key Findings
The study found substantial differences between MSCs from different sources, particularly between iPSC-derived MSCs and those from bone marrow or adipose tissue. iPSC-derived MSCs exhibited more consistent batch variability and released more unique proteins, suggesting additional therapeutic effects. Additionally, iPSC-derived and umbilical cord-derived MSCs displayed characteristics of “younger” cells, maintaining regenerative potential under both resting and inflammatory conditions. In vitro analyses revealed that iPSC-derived MSCs promoted faster wound closure and demonstrated superior immunomodulatory effects compared to MSCs from other sources.
Executive Comments
Dr Kilian Kelly, Cynata’s Chief Executive Officer and Managing Director, stated, “This robust and comprehensive study provides further support for our view that our iPSC-based Cymerus™ platform provides the ideal means of producing MSCs with a high level of potency and functionality, in a consistent and scalable manner. It is particularly notable that Cynata’s iPSC-derived MSCs displayed very impressive immunomodulatory and wound-healing properties compared to MSCs from other sources. These findings have clear relevance to our product candidates in acute graft versus host disease and diabetic foot ulcers, both of which have already shown very promising safety and efficacy outcomes in completed clinical trials.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.